Literature DB >> 18702172

A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma.

S Boeuf1, P Kunz, T Hennig, B Lehner, Pcw Hogendoorn, Jvmg Bovée, W Richter.   

Abstract

Phenotypic and molecular parallels between the development of chondrosarcoma and the differentiation of chondrocytes in normal growth plate suggest that chondrosarcoma may arise from mesenchymal precursor cells driven towards chondrogenesis. We hypothesized that a comparison between cartilaginous tumours and their possible physiological cells of origin, mesenchymal stem cells (MSCs), might have biological and clinical relevance. MSCs from eight donors were submitted to chondrogenic differentiation in spheroid cultures. Expression profiles of MSCs at days 0, 7, 14, 28 and 42 of chondrogenesis and of 18 chondrosarcomas with different histological grades were studied using a customized cDNA array. Hierarchical clustering of MSC gene expression during chondrogenesis allowed the classification of samples in a pre-chondrogenic and a chondrogenic cluster corresponding to the phenotypes of early and late differentiation stages. The 74 genes differentially expressed between the two clusters were defined as chondrogenesis-relevant genes. Gene expression profiles of chondrosarcoma were submitted to hierarchical clustering on the basis of these chondrogenesis-relevant genes. This analysis allowed clear distinction between grade I and grade III chondrosarcoma and separated grade II chondrosarcoma into two groups. All grade II chondrosarcomas with occurrence of metastasis were found together with the grade III chondrosarcomas in the pre-chondrogenic cluster. This analysis shows that a molecular approach based on the comparison of tumour samples to an in vitro model for chondrogenic differentiation allows a new classification of chondrosarcoma in two clusters. These data suggest that the identification of a pre-chondrogenic and a chondrogenic phenotype for chondrosarcoma by gene expression profiling could develop into a useful tool to predict the clinical behaviour of chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702172     DOI: 10.1002/path.2389

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Authors:  Jilong Yang; Zhiwu Ren; Xiaoling Du; Mengze Hao; Wenya Zhou
Journal:  Stem Cell Investig       Date:  2014-10-27

3.  Mesenchymal Stem Cells: Miraculous Healers or Dormant Killers?

Authors:  Abbas Ghaderi; Shabnam Abtahi
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

4.  Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation.

Authors:  A S Landman; P S Danielian; J A Lees
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

5.  Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma.

Authors:  Ning Lu; Tao Lin; Lin Wang; Mei Qi; Zhiyan Liu; Hongyan Dong; Xiying Zhang; Chunyan Zhai; Yan Wang; Long Liu; Lei Xiang; Lei Qi; Bo Han; Jinsong Li
Journal:  Tumour Biol       Date:  2015-01-09

6.  Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.

Authors:  Hendrik Gremmels; Martin Teraa; Paul Ha Quax; Krista den Ouden; Joost O Fledderus; Marianne C Verhaar
Journal:  Mol Ther       Date:  2014-09-01       Impact factor: 11.454

Review 7.  In vitro three-dimensional cell cultures for bone sarcomas.

Authors:  Javier Munoz-Garcia; Camille Jubelin; Aurélie Loussouarn; Matisse Goumard; Laurent Griscom; Axelle Renodon-Cornière; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2021-07-06       Impact factor: 4.072

8.  The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.

Authors:  E David; F Blanchard; M F Heymann; G De Pinieux; F Gouin; F Rédini; D Heymann
Journal:  Sarcoma       Date:  2011-05-22

9.  The HPB-AML-I cell line possesses the properties of mesenchymal stem cells.

Authors:  Bambang Ardianto; Takeshi Sugimoto; Seiji Kawano; Shimpei Kasagi; Siti N A Jauharoh; Chiyo Kurimoto; Eiji Tatsumi; Keiko Morikawa; Shunichi Kumagai; Yoshitake Hayashi
Journal:  J Exp Clin Cancer Res       Date:  2010-12-13

10.  BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors.

Authors:  Stephane Boeuf; Judith V M G Bovée; Burkhard Lehner; Brendy van den Akker; Maayke van Ruler; Anne-Marie Cleton-Jansen; Wiltrud Richter
Journal:  BMC Cancer       Date:  2012-10-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.